Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories


Lexeo stacks up $85m
Weill Cornell Medicine‘s monogenic diseases therapy developer Lexeo Therapeutics has made its public debut with $85m in series A financing.
LifeMine Therapeutics lands $50m
LifeMine’s chairman and co-founder Rick Klausner has co-led a round that included multiple corporates and pushed the overall equity to $120m.
Carisma motivates investors for $47m series B
IP Group was among the investors for UPenn-founded cancer immunotherapy developer Carisma Therapeutics, which has now raised nearly $109m altogether.
Werewolf wins over UPMC for series B
UPMC Enterprise has returned for a $72m series B round raised by Werewolf Therapeutics, which is now set to advance two lead assets through phase 1 trials.
Dice Molecules determines series C investors
Osage University Partners has contributed to an $80m round for Dice Molecules, which is advancing Stanford University research and is also backed by Sanofi and Alexandria.
AMP Robotics accesses $55m in series B
UC-backed Congruent Ventures has contributed to a $55m round that will support the recycling robot maker's expansion plans.
The Engine helps pour $50m into Boston Metal
Boston Metal is most of the way to a $60m target for its latest round, thanks to a consortium that included returning backer The Engine.
Oxbotica takes series B for a $47m spin
University of Oxford’s autonomous driving software developer Oxbotica has secured $47m in a series B round featuring IP Group as well as several corporates.

Other News

IconOVir Bio conducts $77m series A
The oncolytic virus therapy-based cancer drug developer is based on research at Salk Institute and has raised $77m in its series A round.
Superpedestrian soars with $60m
Citi Impact Fund helped supply $60m to help MIT’s smart scooter provider Superpedestrian hike its overall funding to about $140m.
Gojo finds series D mojo
Tokyo University of Science helped extend Gojo & Company's series D round to $68.6m, lifting the microfinancing provider's overall funding to around $142m.
Atsena actions $55m series A
University of Florida has backed a second round for Atsena, a vision loss therapy developer exploiting inventions the institution had originally licensed to Sanofi.
Faze Medicines fades in with $81m
The neurodegenerative disorder drug developer has emerged from stealth to commercialise Howard Hughes Medical Institute research.
Isar Aerospace rockets to series B
The rocket launcher spinout of TUM has received $90.8m in a UVC Partners-backed round as it prepares for a first commercial launch in 2022.

Editor's Picks

Big deal: Oxford PV begins capturing series D
Goldwind, Legal & General and Equinor have all taken part in a series D that achieved a $41m first close and boosted the Oxford spinout’s total equity and debt to more than $118m.
Big deal: Ribon ties together $65m series B
Ribon Therapeutics has emerged out of stealth after three years of developing a lead asset targeting cancer based on research at MIT, UT Southwestern and Harvard Medical School.
Big deal: NMD flexes series A muscles
Aarhus University spinout NMD Pharma, which focuses on therapies for neuromuscular conditions, has attracted the support of several corporates for its $47m series A round.
Big deal: Touchstone helps inject $73m into Cell Medica
Touchstone Innovations, which co-founded the cellular immunotherapy developer in 2007, has contributed to another funding round.
test reg